Nesyrgy (Amlodipine Besilate, Nebivolol Hydrochloride)

Amlodipine besilate, the active ingredient in Nesyrgy, is a calcium‑channel blocker presented as an oral tablet for oral use. It is combined with nebivolol hydrochloride, a selective β1‑blocker, to lower elevated blood pressure in adult patients with hypertension. The combination is approved in the European Union and is indicated for patients who require dual therapy to achieve target blood pressure. GNH USA supplies Nesyrgy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, and adheres to stringent quality standards for export.

Nesyrgy, containing amlodipine besilate and nebivolol hydrochloride, is used in the management of hypertension, a cardiovascular condition characterized by elevated arterial pressure.

Hypertension: lowers systolic and diastolic blood pressure to target levels. Essential hypertension: provides combined calcium‑channel blocker and β‑blocker therapy for patients uncontrolled on monotherapy. Stage 2 hypertension: offers dual mechanism to achieve guideline‑recommended blood pressure goals.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or lower legs. - Flushing: transient warmth and redness. - Dizziness or light‑headedness, especially after standing. - Fatigue: general tiredness. - Palpitations: awareness of heartbeat.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Bradycardia: abnormally slow heart rate. - Atrioventricular block: impaired electrical conduction. - Hepatic injury: signs of liver dysfunction. - Allergic reactions: rash, itching, or hives. - Angioedema: swelling of face, lips, tongue, or throat.

Before initiating therapy, clinicians should consider patient‑specific factors and monitor for adverse events.

Monitor blood pressure: ensure adequate control without excessive lowering. Assess cardiac function: evaluate for bradycardia or conduction abnormalities. Review concomitant antihypertensives: adjust doses to avoid additive hypotension. Caution in hepatic impairment: dose may need adjustment. Avoid abrupt discontinuation: taper to prevent rebound hypertension. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nesyrgy may interact with several medicines; careful review is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma levels. - Other antihypertensives (e.g., ACE inhibitors, diuretics): additive blood‑pressure reduction. - Non‑dihydropyridine calcium‑channel blockers (e.g., verapamil): risk of severe bradycardia. - Beta‑blockers (e.g., propranolol): excessive β‑blockade. - Grapefruit juice: may raise amlodipine concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance electrolyte disturbances. - NSAIDs: can blunt antihypertensive effect. - Antidiabetic agents: blood‑glucose control may change, requiring monitoring.